India

Our work in India has been related to the identification of high-priority cancer medicines amongst oncologists in the nation, identifying challenges and opportunities in conducting clinical trials in LMICs, choosing cost-effective, high-value treatments, and minimizing the effects of financial toxicity. In India, we partner with colleagues from Tata Medical Center in Kolkata. In addition, Dr. Gyawali is the planning member for annual ecancer India Meetings in Mumbai and Kolkata.

Relevant Publications:

  1. Koczwara B, Chan A, Jefford M, Lam WWT, Taylor C, Wakefield CE, Bhoo-Pathy N, Gyawali B, Harvet G, Lou Y, Pramesh CS, Takahashi M, Ke Y, Chan RJ. Cancer Survivorship in the Indo-Pacific: Priorities for Progress. JCO Glob Oncol. 2023. PMID: 36749908.
  2. Akhade A, Gyawali B, Sullivan R, Sirohi B (2022). Highlights from the Choosing Wisely 2022 for Resource Limited Settings: Reducing Low Value Cancer Care for Sustainability conference, 17th–18th September, Mumbai, India ecancer 16 1465. PMID: 36819800
  3. Sengar M, Fundytus A, Hopman W, Pramesh CS, Radhakrishnan V, Ganesan P, Mathew A, Lombe D, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Cancer Medicines: What Is Essential and Affordable in India? JCO Glob Oncol. 2022 Jul;8:e2200060. PMID: 35853192.
  4. Datta SS, Mukherjee A, Ghose S, Bhattacharya S, Gyawali B. Addressing the Mental Health Challenges of Cancer Care Workers in LMICs During the Time of the COVID-19 Pandemic.JCO Glob Oncol. 2020. PMID: 33017180
  5. Gyawali B*, Bouche G, Crisp N. and Andre N. Challenges and opportunities for cancer clinical trials in low- and middle-income countries. Nature Cancer 1, 142–145 (2020). Altmetric score: 135
  6. Gyawali B*, Shimokata T, Honda K, Tsukuura T and Ando Y. Should low-income countries spend on breast-cancer screening? Cancer Causes and Control (2016) 27:1341. (PMID: 27680017)